|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM366335618 |
| 003 |
DE-627 |
| 005 |
20240410232345.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231227s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109879
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1371.xml
|
| 035 |
|
|
|a (DE-627)NLM366335618
|
| 035 |
|
|
|a (NLM)38142901
|
| 035 |
|
|
|a (PII)S1521-6616(23)00643-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Huan, Xiao
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections
|b A prospective cohort study
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.01.2024
|
| 500 |
|
|
|a Date Revised 10.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a The impact of Omicron infections on the clinical outcome and immune responses of myasthenia gravis (MG) remained largely unknown. From a prospective multicenter MG cohort (n = 189) with 197 myasthenic crisis (MC), we finally included 41 independent MG patients to classify into two groups: the Omicron Group (n = 13) and the Control Group (n = 28). In this matched cohort study, all-cause mortality was 7.69% (1/13) in Omicron Group and 14.29% (4/28) in Control Group. A higher proportion of elevated serum IL-6 was identified in the Omicron Group (88.89% vs 52.38%, P = 0.049). In addition, the proportions of CD3+CD8+T in lymphocytes and Tregs in CD3+CD4+ T cells were significantly elevated in the Omicron Group (both P = 0.0101). After treatment, the Omicron Group exhibited a marked improvement in MG-ADL score (P = 0.026) and MG-QoL-15 (P = 0.0357). MCs with Omicron infections were associated with elevated serum IL-6 and CD3+CD8+T response. These patients tended to present a better therapeutic response after fast-acting therapies and anti-IL-6 treatment
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Clinical outcome
|
| 650 |
|
4 |
|a Interleukin-6
|
| 650 |
|
4 |
|a Myasthenic crisis
|
| 650 |
|
4 |
|a Omicron infections
|
| 650 |
|
4 |
|a Peripheral immune
|
| 650 |
|
7 |
|a Interleukin-6
|2 NLM
|
| 700 |
1 |
|
|a Chen, Jialin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhong, Huahua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Yafang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Haoqin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Song, Jie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yan, Chong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xi, Jianying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zou, Zhangyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zheng, Jianming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ruan, Zhe
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tan, Song
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Lijun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Sushan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Chongbo
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a Pan-Yangtze River Delta Alliance for Neuromuscular Disorders (PYDAN)
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 259(2024) vom: 29. Feb., Seite 109879
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:259
|g year:2024
|g day:29
|g month:02
|g pages:109879
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109879
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 259
|j 2024
|b 29
|c 02
|h 109879
|